Literature DB >> 28736564

Characterization of an Animal Model to Study Risk Factors and New Therapies for the Cardiorenal Syndrome, a Major Health Issue in Our Aging Population.

Anja Verhulst1, Ellen Neven1, Patrick C D'Haese1.   

Abstract

BACKGROUND: The cardiorenal syndrome (CRS) is a major health problem in our aging population. The term was introduced to cover disorders of the kidneys and heart, whereby dysfunction of one organ may induce dysfunction of the other. As the natural history of the CRS is mostly slow, hence difficult to explore in clinical trials, adequate animal models combining cardiovascular and renal disease are required. Therefore, we developed and characterized a usable model for CRS type 4, i.e. chronic kidney disease (CKD) causing cardiac dysfunction.
METHODS: CKD was induced in rats by supplementing the diet with adenine. During 8 weeks, several aspects of CRS were studied: CKD, mineral-bone disorder (MBD), cardiovascular disease, and (iron-deficiency) anemia. Hereto, the following parameters were monitored: serum creatinine, calcium, phosphate, FGF23, dynamic bone parameters, aortic Ca deposits, heart weight, serum NT-proANP, Hct, Hb, reticulocytes, spleen iron, and serum hepcidin.
RESULTS: Animals developed a severe CKD together with a disturbed mineral balance as reflected by the increased serum creatinine and phosphorus levels and decreased serum calcium levels; and in association herewith aberrations in hormonal levels of FGF-23. In turn, the well-known and highly undesirable complications of CKD, i.e. high turnover bone disease and pathological vessel calcification were induced. Furthermore (iron-deficiency) anemia developed quickly.
CONCLUSION: The animal model described in this article in many aspects mimics the human situation of the CRS type 4 and will be useful to concomitantly evaluate the effects of new treatment strategies on the various aspects of CRS.

Entities:  

Keywords:  Anemia; Bone and mineral metabolism; Cardiovascular disease

Year:  2017        PMID: 28736564      PMCID: PMC5511997          DOI: 10.1159/000462984

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  31 in total

1.  NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life.

Authors:  G Thibault; K K Murthy; J Gutkowska; N G Seidah; C Lazure; M Chrétien; M Cantin
Journal:  Peptides       Date:  1988 Jan-Feb       Impact factor: 3.750

2.  Hepcidin and disordered mineral metabolism in chronic kidney disease.

Authors:  C Carvalho; T Isakova; G Collerone; G Olbina; M Wolf; M Westerman; O M Gutiérrez
Journal:  Clin Nephrol       Date:  2011-08       Impact factor: 0.975

3.  Atrial natriuretic peptides in Han Wistar, Sprague-Dawley and spontaneously hypertensive rats.

Authors:  Federica Crivellente; Nicola Bocchini; Monica Bonato; Luca Vandin; Ivo Faustinelli; Patrizia Cristofori
Journal:  J Appl Toxicol       Date:  2011-11-14       Impact factor: 3.446

4.  Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.

Authors:  Noopur Raje; Sonia Vallet
Journal:  Curr Opin Mol Ther       Date:  2010-10

Review 5.  Strategies for developing biomarkers of heart failure.

Authors:  Saeed A Jortani; Sumanth D Prabhu; Roland Valdes
Journal:  Clin Chem       Date:  2003-12-04       Impact factor: 8.327

6.  A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.

Authors:  Chia Chi Sun; Valentina Vaja; Shanzhuo Chen; Igor Theurl; Aaron Stepanek; Diane E Brown; Maria D Cappellini; Guenter Weiss; Charles C Hong; Herbert Y Lin; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-01-22       Impact factor: 5.992

7.  Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study.

Authors:  Eyal Ben-Assa; Yacov Shacham; Moshe Shashar; Eran Leshem-Rubinow; Amir Gal-Oz; Idit F Schwartz; Doron Schwartz; Donald S Silverberg; Gil Chernin
Journal:  Cardiorenal Med       Date:  2015-07-04       Impact factor: 2.041

8.  Variability of Nt-proANP and C-ANP.

Authors:  G McDowell; C Patterson; S Maguire; C Shaw; D P Nicholls; C Hall
Journal:  Eur J Clin Invest       Date:  2002-08       Impact factor: 4.686

Review 9.  Cardiorenal syndrome.

Authors:  Claudio Ronco; Mikko Haapio; Andrew A House; Nagesh Anavekar; Rinaldo Bellomo
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

10.  Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status.

Authors:  Josep Comín-Colet; Cristina Enjuanes; Gina González; Ainhoa Torrens; Mercè Cladellas; Oona Meroño; Nuria Ribas; Sonia Ruiz; Miquel Gómez; José Maria Verdú; Jordi Bruguera
Journal:  Eur J Heart Fail       Date:  2013-05-22       Impact factor: 15.534

View more
  2 in total

1.  Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers.

Authors:  Antonia E Schantl; Anja Verhulst; Ellen Neven; Geert J Behets; Patrick C D'Haese; Marc Maillard; David Mordasini; Olivier Phan; Michel Burnier; Dany Spaggiari; Laurent A Decosterd; Mark G MacAskill; Carlos J Alcaide-Corral; Adriana A S Tavares; David E Newby; Victoria C Beindl; Roberto Maj; Anne Labarre; Chrismita Hegde; Bastien Castagner; Mattias E Ivarsson; Jean-Christophe Leroux
Journal:  Nat Commun       Date:  2020-02-05       Impact factor: 14.919

Review 2.  The Multifunctional Contribution of FGF Signaling to Cardiac Development, Homeostasis, Disease and Repair.

Authors:  Farhad Khosravi; Negah Ahmadvand; Saverio Bellusci; Heinrich Sauer
Journal:  Front Cell Dev Biol       Date:  2021-05-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.